_id
69104fe9ccc777a4e85d53ca
Ticker
CLNN
Name
Clene Inc.
Exchange
NASDAQ
Address
6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
Country
USA
Sector
Consumer Defensive
Industry
Packaged Foods
Currency
USD
Website
https://clene.com
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Last Close
6.88
Volume
55583
Current Price
6.78
Change
-1.453488372093018
Last Updated
2025-11-29T11:33:24.162Z
Image
data:image/webp;base64,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
Ipo Date
2020-12-31T00:00:00.000Z
Market Cap
107060032
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.259
Sentiment Sources
2
Rating
4.5
Target Price
30.4286
Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
15000
Cost Of Revenue
0
Gross Profit
15000
Operating Expenses
5663000
Operating Income
-5648000
Interest Expense
649000
Pretax Income
-8777000
Net Income
-8777000
Eps
-0.8534057569544742
Dividends Per Share
-
Shares Outstanding
10333980
Income Tax Expense
-
EBITDA
-7763000
Operating Margin
-37653.333333333336
Total Other Income Expense Net
-3129000
Cash
7925000
Short Term Investments
-
Receivables
550000
Inventories
61000
Total Current Assets
12673000
Property Plant Equipment
9580000
Total Assets
22311000
Payables
1369000
Short Term Debt
2043000
Long Term Debt
15785000
Total Liabilities
34668000
Equity
-12357000
Depreciation
365000
Change In Working Capital
-420125
Cash From Operations
-3975140
Capital Expenditures
10969
Cash From Investing
-10974
Cash From Financing
4627403
Net Change In Cash
640000
PE
-
PB
-5.642962670551104
ROE
71.02856680424051
ROA
-39.33933933933934
FCF
-3986109
Fcf Percent
-265.7406
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
0.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
4
Net Net Investing Score
0.5
Quality Investing Score
2.5
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
15000
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
15000
Quarters > 0 > income Statement > operating Expenses
5663000
Quarters > 0 > income Statement > operating Income
-5648000
Quarters > 0 > income Statement > interest Expense
649000
Quarters > 0 > income Statement > pretax Income
-8777000
Quarters > 0 > income Statement > net Income
-8777000
Quarters > 0 > income Statement > eps
-0.8534057569544742
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
10284674
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-7763000
Quarters > 0 > income Statement > operating Margin
-37653.333333333336
Quarters > 0 > income Statement > total Other Income Expense Net
-3129000
Quarters > 0 > balance Sheet > cash
7925000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
550000
Quarters > 0 > balance Sheet > inventories
61000
Quarters > 0 > balance Sheet > total Current Assets
12673000
Quarters > 0 > balance Sheet > property Plant Equipment
9580000
Quarters > 0 > balance Sheet > total Assets
22311000
Quarters > 0 > balance Sheet > payables
1369000
Quarters > 0 > balance Sheet > short Term Debt
2043000
Quarters > 0 > balance Sheet > long Term Debt
15785000
Quarters > 0 > balance Sheet > total Liabilities
34668000
Quarters > 0 > balance Sheet > equity
-12357000
Quarters > 0 > cash Flow > net Income
-8777000
Quarters > 0 > cash Flow > depreciation
365000
Quarters > 0 > cash Flow > change In Working Capital
-420125
Quarters > 0 > cash Flow > cash From Operations
-3975140
Quarters > 0 > cash Flow > capital Expenditures
10969
Quarters > 0 > cash Flow > cash From Investing
-10974
Quarters > 0 > cash Flow > cash From Financing
4627403
Quarters > 0 > cash Flow > net Change In Cash
640000
Quarters > 0 > ratios > PE
-0.8534057569544742
Quarters > 0 > ratios > PB
-5.642962670551104
Quarters > 0 > ratios > ROE
71.02856680424051
Quarters > 0 > ratios > ROA
-39.33933933933934
Quarters > 0 > ratios > FCF
-3986109
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-265.7406
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
27000
Quarters > 1 > income Statement > cost Of Revenue
366000
Quarters > 1 > income Statement > gross Profit
27000
Quarters > 1 > income Statement > operating Expenses
5891000
Quarters > 1 > income Statement > operating Income
-5864000
Quarters > 1 > income Statement > interest Expense
679000
Quarters > 1 > income Statement > pretax Income
-7419000
Quarters > 1 > income Statement > net Income
-7419000
Quarters > 1 > income Statement > eps
-0.7790127926521841
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
9523592
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-6374000
Quarters > 1 > income Statement > operating Margin
-21718.51851851852
Quarters > 1 > income Statement > total Other Income Expense Net
-1555000
Quarters > 1 > balance Sheet > cash
7285000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
1319000
Quarters > 1 > balance Sheet > inventories
79000
Quarters > 1 > balance Sheet > total Current Assets
11985000
Quarters > 1 > balance Sheet > property Plant Equipment
10082000
Quarters > 1 > balance Sheet > total Assets
22125000
Quarters > 1 > balance Sheet > payables
828000
Quarters > 1 > balance Sheet > short Term Debt
1387000
Quarters > 1 > balance Sheet > long Term Debt
15753000
Quarters > 1 > balance Sheet > total Liabilities
30675000
Quarters > 1 > balance Sheet > equity
-8550000
Quarters > 1 > cash Flow > net Income
-7419000
Quarters > 1 > cash Flow > depreciation
366000
Quarters > 1 > cash Flow > change In Working Capital
-420000
Quarters > 1 > cash Flow > cash From Operations
-4744000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
2133000
Quarters > 1 > cash Flow > net Change In Cash
-2547000
Quarters > 1 > ratios > PE
-0.7790127926521841
Quarters > 1 > ratios > PB
-7.552041375438597
Quarters > 1 > ratios > ROE
86.7719298245614
Quarters > 1 > ratios > ROA
-33.53220338983051
Quarters > 1 > ratios > FCF
-4744000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-175.7037037037037
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
81000
Quarters > 2 > income Statement > cost Of Revenue
20000
Quarters > 2 > income Statement > gross Profit
61000
Quarters > 2 > income Statement > operating Expenses
4137000
Quarters > 2 > income Statement > operating Income
-4076000
Quarters > 2 > income Statement > interest Expense
608000
Quarters > 2 > income Statement > pretax Income
-751000
Quarters > 2 > income Statement > net Income
-751000
Quarters > 2 > income Statement > eps
-0.08510230350745007
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
8824673
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
261000
Quarters > 2 > income Statement > operating Margin
-5032.098765432099
Quarters > 2 > income Statement > total Other Income Expense Net
3325000
Quarters > 2 > balance Sheet > cash
9832000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1511000
Quarters > 2 > balance Sheet > inventories
38000
Quarters > 2 > balance Sheet > total Current Assets
14671000
Quarters > 2 > balance Sheet > property Plant Equipment
10585000
Quarters > 2 > balance Sheet > total Assets
25314000
Quarters > 2 > balance Sheet > payables
1413000
Quarters > 2 > balance Sheet > short Term Debt
4106000
Quarters > 2 > balance Sheet > long Term Debt
12913000
Quarters > 2 > balance Sheet > total Liabilities
30287000
Quarters > 2 > balance Sheet > equity
-4973000
Quarters > 2 > cash Flow > net Income
-751000
Quarters > 2 > cash Flow > depreciation
404000
Quarters > 2 > cash Flow > change In Working Capital
-3336000
Quarters > 2 > cash Flow > cash From Operations
-5011000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
2673000
Quarters > 2 > cash Flow > net Change In Cash
-2323000
Quarters > 2 > ratios > PE
-0.08510230350745007
Quarters > 2 > ratios > PB
-12.031225204102151
Quarters > 2 > ratios > ROE
15.101548361150211
Quarters > 2 > ratios > ROA
-2.9667377735640357
Quarters > 2 > ratios > FCF
-5011000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-61.864197530864196
Quarters > 2 > health Score
26
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
91000
Quarters > 3 > income Statement > cost Of Revenue
18000
Quarters > 3 > income Statement > gross Profit
73000
Quarters > 3 > income Statement > operating Expenses
8728000
Quarters > 3 > income Statement > operating Income
-8655000
Quarters > 3 > income Statement > interest Expense
516000
Quarters > 3 > income Statement > pretax Income
-13549000
Quarters > 3 > income Statement > net Income
-13549000
Quarters > 3 > income Statement > eps
-1.9483377726597981
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
6954133
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-12628000
Quarters > 3 > income Statement > operating Margin
-9510.989010989011
Quarters > 3 > income Statement > total Other Income Expense Net
-4894000
Quarters > 3 > balance Sheet > cash
12155000
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
391000
Quarters > 3 > balance Sheet > inventories
68000
Quarters > 3 > balance Sheet > total Current Assets
16157000
Quarters > 3 > balance Sheet > property Plant Equipment
11122000
Quarters > 3 > balance Sheet > total Assets
27337000
Quarters > 3 > balance Sheet > payables
1240000
Quarters > 3 > balance Sheet > short Term Debt
1285000
Quarters > 3 > balance Sheet > long Term Debt
15426000
Quarters > 3 > balance Sheet > total Liabilities
36194000
Quarters > 3 > balance Sheet > equity
-8857000
Quarters > 3 > cash Flow > net Income
-13549000
Quarters > 3 > cash Flow > depreciation
405000
Quarters > 3 > cash Flow > change In Working Capital
1637000
Quarters > 3 > cash Flow > cash From Operations
-4865000
Quarters > 3 > cash Flow > capital Expenditures
1000
Quarters > 3 > cash Flow > cash From Investing
-2000
Quarters > 3 > cash Flow > cash From Financing
2528000
Quarters > 3 > cash Flow > net Change In Cash
-2490000
Quarters > 3 > ratios > PE
-1.9483377726597981
Quarters > 3 > ratios > PB
-5.323362508750141
Quarters > 3 > ratios > ROE
152.97504798464493
Quarters > 3 > ratios > ROA
-49.56286351830852
Quarters > 3 > ratios > FCF
-4866000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-53.472527472527474
Quarters > 3 > health Score
31
Valuation > metrics > PE
-0.8534057569544742
Valuation > metrics > PB
-5.642962670551104
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
71.02856680424051
Profitability > metrics > ROA
-69.25747652489545
Profitability > metrics > Net Margin
-585.1333333333333
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-8.702619414483822
Risk > final Score
-5
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.7142438452520516
Liquidity > metrics > Quick Ratio
3.6963657678780772
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
40
Prev Profitabilities > 1
30
Prev Profitabilities > 2
40
Prev Risks > 0
-5
Prev Risks > 1
3
Prev Risks > 2
-37
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:32:14.287Z
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Fed Impact: How CLNN stock reacts to bond yields - July 2025 Gainers & Real-Time Volume Analysis Alerts moha.gov.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$30.4286
Analyst Picks
Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 2.63% of the total shares of Clene Inc.
1.
NT Ext Equity Mkt Idx Fd - DC - NL - T2(1.8059%)
since
2024/06/30
2.
NT Ext Eq Mkt Indx Fd DC Lending Tier 5(0.6519%)
since
2024/06/30
3.
BNYM Mellon SL Market Completion UC1(0.1612%)
since
2024/06/30
4.
BNYM Mellon NSL Mkt Completion Fund Inst(0.0097%)
since
2024/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.